EGFR and neoplasm: One of the mechanisms contributing to resistance to EGFR TKIs, notably at diagnosis, is the amplification of the EGFR gene (EGFR-amp), leading to increased protein expression and activation of downstream signalling pathways that promote tumour growth and survival [17].